ArticleMolecular psychiatry2026
Exploring the impact of cognitive profiles on the response to magnetic seizure therapy and electroconvulsive therapy.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Re-evaluating response rates, time to reorientation and inadequate seizure duration in magnetic seizure therapy for schizophrenia and major depression.Molecular psychiatry · 2026Article
- Comparative efficacy and cognitive function of magnetic seizure therapy and electroconvulsive therapy for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) are effective treatments for schizophrenia (SCZ) and major depressive disorder (MDD), with MST offering advantages in preserving cognitive function. Although cognitive profiles are known to influence treatment outcomes, their role in moderating response to seizure therapies remains unclear. We conducted an open-label, non-randomized controlled trial to compare the efficacy of MST and ECT across different cognitive profiles. From October 2020 to June 2024, we recruited 263 patients with SCZ and 135 patients with MDD, identifying cognitive profiles through latent profile analysis. Among them, 54 patients with SCZ and 119 patients with MDD received MST or ECT, completing 3 or 4 sessions per week. MST was administered at 100% device output and 100 Hz over the vertex. Treatment effectiveness was measured using the Positive and Negative Syndrome Scale and the 24-item Hamilton Depression Rating Scale, while cognitive function with the MATRICS Consensus Cognitive Battery. We analyzed outcomes trajectories using a linear mixed-effects model. Results indicated significant symptom score reductions for both MST and ECT. MST provided better cognitive benefits, especially in information processing speed. Among cognitive profiles, the Optimal-Cognition Group in SCZ receiving ECT showed the strongest symptom reduction, while the Poor-Cognition Group in MDD receiving ECT exhibited the greatest symptom reduction. In contrast, MST had comparable treatment effects on both cognitive groups in SCZ and MDD. In conclusion, MST and ECT yielded similar clinical outcomes, but MST provided better cognitive protective advantages; baseline cognitive profiles appeared to influence ECT outcomes, whereas MST effects were relatively consistent across cognitive profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.